AR057072A1 - Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto - Google Patents
Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuestoInfo
- Publication number
- AR057072A1 AR057072A1 ARP060102611A ARP060102611A AR057072A1 AR 057072 A1 AR057072 A1 AR 057072A1 AR P060102611 A ARP060102611 A AR P060102611A AR P060102611 A ARP060102611 A AR P060102611A AR 057072 A1 AR057072 A1 AR 057072A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- aryl
- carbamoyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Los compuestos son utiles como inhibidores de la absorcion del colesterol para el tratamiento de la hiperlipidemia. También se describen procesos para la fabricacion del compuesto, composiciones farmacéuticas que los contienen y compuestos intermediarios. Reivindicacion 1: Un compuesto de formula (1), en la cual: X = -CH2-, -CH2CH2-, - CH2CH2CH2-; R1 = H, alquilo C1-6, cicloalquilo C3-6 o arilo; R2 y R3 es hidrogeno, un alquilo C1-6 recto o ramificado, cicloalquilo C3-6 o arilo; donde dicho alquilo C1-6 puede estar sustituido en forma opcional con uno o más hidroxi, amino, guanidino, carbamoilo, carboxi, alcoxi C1-6, (alquiloC1-4)3Si, N-(alquilC1-6)amino, N,N-(alquilC1-6)2amino, alquiloC1-6S(O)a donde a es 0-2, cicloalquilo C3-6 o arilo; y donde cualquier grupo arilo puede estar sustituido en forma opcional con uno o dos sustituyentes seleccionados de halo, hidroxi, ciano, alquilo C1-6 o alcoxi C1-6; R4 es hidrogeno, alquilo C1-6, o arilalquilo C1-6; donde R3 y R2 pueden formar un anillo con C3-7 y donde R4 y R2 pueden formar un anillo con C2-6; R5 se selecciona de hidrogeno, halo, nitro, ciano, hidroxi, carboxi, carbamoilo, sulfamoilo, alquilo C1-6, alcoxi C1-6, alcanooilo C1-6, alcanoiloxi C1-6, N-(alquilC1- 6)amino, N,N-(alquilC1-6)2amino, alcanoilamino C1-6, N-(alquilC1-6)carbamoilo, N,N-(alquilC1-6)2carbamoilo, alquilC1-6S(O)a, donde a es 0 a 2, alcoxicarbonilo C1-6, N-(alquilC1-6)sulfamoilo y N,N-(alquilC1-6)2sulfamoilo; y donde n es 0, 1, 2 o 3; o una de sus sales, solvatos de dicha sal o profármaco aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0501464 | 2005-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057072A1 true AR057072A1 (es) | 2007-11-14 |
Family
ID=37570735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102611A AR057072A1 (es) | 2005-06-22 | 2006-06-20 | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
Country Status (20)
Country | Link |
---|---|
US (1) | US7906502B2 (es) |
EP (1) | EP1896459A4 (es) |
JP (1) | JP2008546774A (es) |
KR (1) | KR20080017475A (es) |
CN (1) | CN101243076A (es) |
AR (1) | AR057072A1 (es) |
AU (1) | AU2006259898B2 (es) |
BR (1) | BRPI0612109A2 (es) |
CA (1) | CA2610036A1 (es) |
EC (1) | ECSP078051A (es) |
IL (1) | IL187741A0 (es) |
MX (1) | MX2007016398A (es) |
MY (1) | MY148538A (es) |
NO (1) | NO20076138L (es) |
RU (1) | RU2409572C2 (es) |
SA (1) | SA06270197B1 (es) |
TW (1) | TW200728302A (es) |
UY (1) | UY29613A1 (es) |
WO (1) | WO2006137797A1 (es) |
ZA (1) | ZA200710604B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA04250427A (ar) | 2003-12-23 | 2005-12-03 | استرازينيكا ايه بي | مشتقات ثاني فينيل أزيتيدون |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
EP2133347A4 (en) * | 2007-03-06 | 2010-03-17 | Teijin Pharma Ltd | 1-BIARYLAZETIDINONDERIVATE |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US9212175B2 (en) | 2009-03-06 | 2015-12-15 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
BR112012003973A2 (pt) | 2009-08-26 | 2015-09-08 | Sanofi Sa | hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
RS51449B (sr) | 2001-01-26 | 2011-04-30 | Schering Corporation | Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
ATE345793T1 (de) | 2001-09-21 | 2006-12-15 | Schering Corp | Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption |
DE60229406D1 (de) | 2001-09-21 | 2008-11-27 | Schering Corp | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) |
US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US6761509B2 (en) | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
US6960047B2 (en) | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
JP2006508189A (ja) | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 自己免疫障害の処置のためのコレステロール吸収インヒビター |
US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
WO2004099132A2 (en) | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Process for the preparation of trans-isomers of diphenylazetidinone derivatives |
US20040259179A1 (en) | 2003-05-30 | 2004-12-23 | Gerd Assmann | Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US7002008B2 (en) | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
EP1660456A2 (en) | 2003-08-25 | 2006-05-31 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
EP1660446A2 (en) | 2003-08-28 | 2006-05-31 | Microbia, Inc. | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones |
EP1522541A1 (en) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
EP1682117A1 (en) | 2003-10-30 | 2006-07-26 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
JP2007510659A (ja) | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 |
CA2545058A1 (en) | 2003-11-10 | 2005-05-26 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
WO2005049592A1 (en) | 2003-11-24 | 2005-06-02 | Hetero Drugs Limited | A novel process for ezetimibe intermediate |
US20070099891A1 (en) | 2003-12-17 | 2007-05-03 | Kouichi Kino | Medicinal compositions and combinations |
SA04250427A (ar) | 2003-12-23 | 2005-12-03 | استرازينيكا ايه بي | مشتقات ثاني فينيل أزيتيدون |
CN100471835C (zh) | 2003-12-23 | 2009-03-25 | 默克公司 | 抗高胆固醇血症化合物 |
WO2005062897A2 (en) | 2003-12-23 | 2005-07-14 | Dr. Reddy's Laboratories Ltd. | Polymorphs of ezetimibe and processes for the preparation thereof |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
WO2005066120A2 (en) | 2003-12-30 | 2005-07-21 | Ranbaxy Laboratories Limited | Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives |
WO2005069900A2 (en) | 2004-01-16 | 2005-08-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
RS20060437A (en) | 2004-01-20 | 2008-11-28 | Panacea Boitec Ltd., | Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
KR100725758B1 (ko) * | 2004-03-30 | 2007-06-08 | 삼성광주전자 주식회사 | 전동 송풍기 및 이를 이용한 자동차용 전동 과급기 |
CA2567149A1 (en) | 2004-05-21 | 2005-12-01 | Sanofi-Aventis Deutschland Gmbh | Method for producing 1,4-diphenyl azetidinone derivatives |
DE102004025072A1 (de) | 2004-05-21 | 2005-12-15 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten |
WO2006017257A2 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Azetidinone derivatives |
US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
MX2007003732A (es) | 2004-09-29 | 2007-04-23 | Schering Corp | Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1. |
JP2007526251A (ja) | 2004-12-03 | 2007-09-13 | テバ ファーマシューティカル インダストリーズ リミティド | エゼチミベ多形体 |
CA2591564A1 (en) | 2004-12-20 | 2006-06-29 | Schering Corporation | Process for the synthesis of azetidinones |
IL166149A0 (en) | 2005-01-05 | 2006-01-15 | Hadasit Med Res Service | Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity |
EP1851197A2 (en) | 2005-02-09 | 2007-11-07 | Microbia, Inc. | Phenylazetidinone derivatives |
WO2006102674A2 (en) | 2005-03-24 | 2006-09-28 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
BRPI0609614A2 (pt) | 2005-04-04 | 2010-04-20 | Univ Pontificia Catolica Chile | uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar |
JP2008539255A (ja) | 2005-04-26 | 2008-11-13 | マイクロビア インコーポレーテッド | 高コレステロール血症のための4−ビアリーリル−1−フェニルアゼチジン−2−オングルクロニド誘導体 |
EP1877373A2 (en) | 2005-05-05 | 2008-01-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
WO2006122186A2 (en) | 2005-05-10 | 2006-11-16 | Microbia, Inc. | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
US20080200669A1 (en) | 2005-05-11 | 2008-08-21 | Microbia, Inc. | Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones |
JP2008540573A (ja) | 2005-05-13 | 2008-11-20 | マイクロビア インコーポレーテッド | 4−ビアリーリル−1−フェニラゼチジン−2−オン類 |
BRPI0611415A2 (pt) | 2005-05-25 | 2010-09-08 | Microbia Inc | ácidos fosfÈnicos de 4-(bifenilil)azetidin-2-ona e processo para a produção dos mesmos |
AU2006259646A1 (en) | 2005-06-15 | 2006-12-28 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
WO2006134604A1 (en) | 2005-06-15 | 2006-12-21 | Hetero Drugs Limited | Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
EP1893570A4 (en) | 2005-06-22 | 2009-12-23 | Reddy Manne Satynarayana | IMPROVED PROCESS FOR THE PREPARATION OF EZETIMIBE |
AR057380A1 (es) | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
AR054482A1 (es) | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
AR057383A1 (es) | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR056866A1 (es) | 2005-06-22 | 2007-10-31 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto |
AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
EP1741427A1 (en) | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
WO2007008529A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc | Celullar cholesterol absorption modifiers |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
US20100119525A1 (en) | 2005-08-01 | 2010-05-13 | Mount Sinai Schoool Of Medicine Of New York University | Method for extending longevity using npc1l1 antagonists |
CA2615758A1 (en) | 2005-08-01 | 2007-02-08 | Warner-Lambert Company Llc | Novel substituted azetidinones |
WO2007017705A1 (en) | 2005-08-09 | 2007-02-15 | Glenmark Pharmaceuticals Limited | Process for the preparation of azetidinones |
US20070049748A1 (en) | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
BRPI0605934A2 (pt) | 2005-09-08 | 2009-05-26 | Teva Pharma | processos para a preparação de ( 3r, 4s) - 4 - ( (4-benziloxi ) fenil ) - 1 - ( 4 - fluorofenil ) - 3 - ( (s) - 3 - ( 4 - fluorofenil ) - 3 - hidroxipropil) - 2 - azetidinona, um intermediário para a sìntese da ezetimiba |
TW200806623A (en) | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
WO2007058335A1 (en) | 2005-11-15 | 2007-05-24 | Takeda Pharmaceutical Company Limited | Use of tak-475 together with ezetimibe for treating hyperlipidemia |
DE102005055726A1 (de) | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US7498431B2 (en) | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
HUP0501164A2 (en) | 2005-12-20 | 2007-07-30 | Richter Gedeon Nyrt | New industrial process for the production of ezetimibe |
US20070161578A1 (en) | 2005-12-21 | 2007-07-12 | Hwa Joyce J | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist |
TW200811098A (en) * | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
WO2008033431A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders |
EP2133347A4 (en) * | 2007-03-06 | 2010-03-17 | Teijin Pharma Ltd | 1-BIARYLAZETIDINONDERIVATE |
-
2006
- 2006-06-20 AR ARP060102611A patent/AR057072A1/es not_active Application Discontinuation
- 2006-06-20 MY MYPI20062928A patent/MY148538A/en unknown
- 2006-06-21 BR BRPI0612109A patent/BRPI0612109A2/pt not_active IP Right Cessation
- 2006-06-21 MX MX2007016398A patent/MX2007016398A/es not_active Application Discontinuation
- 2006-06-21 UY UY29613A patent/UY29613A1/es unknown
- 2006-06-21 CA CA002610036A patent/CA2610036A1/en not_active Abandoned
- 2006-06-21 US US11/993,463 patent/US7906502B2/en not_active Expired - Fee Related
- 2006-06-21 AU AU2006259898A patent/AU2006259898B2/en not_active Ceased
- 2006-06-21 JP JP2008518088A patent/JP2008546774A/ja active Pending
- 2006-06-21 CN CNA2006800294761A patent/CN101243076A/zh active Pending
- 2006-06-21 EP EP06747955A patent/EP1896459A4/en not_active Withdrawn
- 2006-06-21 KR KR1020087001032A patent/KR20080017475A/ko not_active Application Discontinuation
- 2006-06-21 WO PCT/SE2006/000766 patent/WO2006137797A1/en active Application Filing
- 2006-06-21 SA SA6270197A patent/SA06270197B1/ar unknown
- 2006-06-21 RU RU2007147340/04A patent/RU2409572C2/ru not_active IP Right Cessation
- 2006-06-22 TW TW095122513A patent/TW200728302A/zh unknown
-
2007
- 2007-11-28 IL IL187741A patent/IL187741A0/en unknown
- 2007-11-28 NO NO20076138A patent/NO20076138L/no not_active Application Discontinuation
- 2007-12-05 ZA ZA200710604A patent/ZA200710604B/xx unknown
- 2007-12-26 EC EC2007008051A patent/ECSP078051A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1896459A4 (en) | 2010-03-10 |
BRPI0612109A2 (pt) | 2016-09-06 |
EP1896459A1 (en) | 2008-03-12 |
CA2610036A1 (en) | 2006-12-28 |
RU2007147340A (ru) | 2009-07-27 |
AU2006259898B2 (en) | 2010-08-05 |
IL187741A0 (en) | 2008-03-20 |
UY29613A1 (es) | 2007-01-31 |
ZA200710604B (en) | 2008-12-31 |
WO2006137797A1 (en) | 2006-12-28 |
KR20080017475A (ko) | 2008-02-26 |
US20100168039A1 (en) | 2010-07-01 |
TW200728302A (en) | 2007-08-01 |
RU2409572C2 (ru) | 2011-01-20 |
MY148538A (en) | 2013-04-30 |
ECSP078051A (es) | 2008-01-23 |
CN101243076A (zh) | 2008-08-13 |
AU2006259898A1 (en) | 2006-12-28 |
JP2008546774A (ja) | 2008-12-25 |
MX2007016398A (es) | 2008-03-05 |
SA06270197B1 (ar) | 2010-06-20 |
US7906502B2 (en) | 2011-03-15 |
NO20076138L (no) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
AR054484A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
AR057383A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
AR060623A1 (es) | Compuestos derivados de 2-azetidinona y un metodo de preparacion | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR047339A1 (es) | Derivados de difenilazetidona.proceso de obtencion. | |
EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
EA201791254A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
EA200500203A1 (ru) | Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат | |
NO20053794L (no) | N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine. | |
BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
NO20082389L (no) | 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
EA201000101A1 (ru) | Производные пиримидина 934 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |